2019 International Congress » Other

Date: Monday, September 23, 2019

Time: 1:45pm-3:15pm

Location: Agora 2 West, Level 2

Meeting: 2019 International Congress

1:45pm-3:15pm: A case of hemimasticatory spasm with well therapeutic response to serial injections of botulinum toxin

SK. Yang, JJ. Lin (Changhua County, Taiwan)

1:45pm-3:15pm: A review of interactive voice response systems in Parkinson’s Disease

J. Domingues, T. Guerreiro, D. Branco, A. Rodrigues, R. Bouça-Machado, J. Ferreira (Aveiro, Portugal)

1:45pm-3:15pm: A Study of Microglial Metabolism in Neuroinflammation

T. Domenick, B. Cyr, R. Yost, M. Okun, V. Vedam-Mai (Gainesville, FL, USA)

1:45pm-3:15pm: Agreement Between the GAITRite® Walkway System and the Wearable Inertial Sensor BTS G-Walk® for Measurement of Gait Parameters

H. Horáková, K. Poláková, E. Růžička, H. Brožová (Prague, Czech Republic)

1:45pm-3:15pm: Automated Immunohistochemical Detection of Skin Depositions of Pathological alpha-Synuclein in Idiopathic REM Sleep Behavior Disorder and Parkinsonism

T-S. Tsao, A. Al-Qassabi, A. Racolta, KI. Taylor, W. Zago, RB. Postuma, S. Dziadek (Basel, Switzerland)

1:45pm-3:15pm: Botulinum toxin treatment of muscle spasms in a case of Satoyoshi syndrome

I. Bledsoe (San Francisco, CA, USA)

1:45pm-3:15pm: Can people with Parkinson’s disease rely on their coping capacity over time? A longitudinal study using the Sense of Coherence (SOC) scale

J. Andersson, G-M. Hariz, L. Forsgren (Umeå, Sweden)

1:45pm-3:15pm: Cerebral cavernous malformations and movement disorders

M. Polemikos, E. Hermann, J. Krauss (Hannover, Germany)

1:45pm-3:15pm: Cerebral palsy masqueraders in an adult movement disorder tertiary centre: when to investigate an alternative diagnosis?

S. Duarte, R. Martins, M. Magalhães (Porto, Portugal)

1:45pm-3:15pm: Certification of cause of death in patients with Parkinson’s Disease (PD)

M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Clinical Audit of Hospital Admissions for Parkinson Disease

HL. Lan, LW. Wei, ST. Shu Ting, KY. Kay Yaw, WL. Wing Lok, LT. Louis Cs (Singapore, Singapore)

1:45pm-3:15pm: Clinical Correlates of Genetic and Biomarker Profiles in Patients with Progressive Supranuclear Palsy: Data from the ARISE Study

H. Soares, Z. Jin, N. Fisseha, M. Gold, C. Locke, B. Rendenbach-Mueller, E. Smith, I. Suridjan, A. Vasanthakumar, N. Mendonca (Ludwigshafen, Germany)

1:45pm-3:15pm: Creutzfeld Jacob disease presenting with functional-appearing, bizarre movements without significant cognitive impairment

M. Mcgraw, Z. Grujic, P. Vittal, J. Pallone (Winfield, IL, USA)

1:45pm-3:15pm: CSF levels of NFL (neurofilament light chain) in Parkinsons’ disease patients

E. Papuć, K. Rejdak (Lublin, Poland)

1:45pm-3:15pm: Cultural bias in performance of motor tasks? Comparison between Japanese and German healthy adults

K. Otte, M. Suzuki, H. Röhling, R. Kuroiwa, S. Mansow-Model, M. Mori, H. Zimmermann, AU. Brandt, F. Paul, S. Hirano, S. Kuwabara, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm: Diagnostic journeys of people with Parkinson’s disease in Kenya, sub-Saharan Africa

N. Fothergill Misbah, K. Hampshire, S. Moffatt, J. Kwasa, J. Hooker, R. Walker (Newcastle Upon Tyne, United Kingdom)

1:45pm-3:15pm: Differential Gait Progression in idiopathic Parkinson’s disease with and without freezing of gait

A. Glover, L. Pillai, S. Doerhoff, T. Virmani (Little Rock, AR, USA)

1:45pm-3:15pm: Digital biomarker sensor feature data reflect quality of life judgements (PDQ39) in recently diagnosed Parkinson’s disease patients

F. Lipsmeier, K. Taylor, E. Volkova-Volkmar, H. Staunton, R. Postuma, T. Kilchenmann, D. Wolf, Y. Zhang, WY. Cheng, A. Scotland, J. Schjodt-Eriksen, F. Boess, D. Ness, C. Gossens, A. Post, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: Does information from the Personal KinetiGraph™ (PKG) influence neurologists´ treatment decisions?

M. Sundgren, P. Rousu, A. Johansson (Stockholm, Sweden)

1:45pm-3:15pm: Dopaminergic Neuroregeneration in the Diencephalon of 6-OHDA-Lesioned Adult Zebrafish-Based Parkinson’s Disease Model

Y. Vijayanathan, SM. Lim, MP. Tan, FT. Lim, AB. Abdul Majeed, K. Ramasamy (Kuala Lumpur, Malaysia)

1:45pm-3:15pm: Effect of Balanced Based Torso Weighting on gait in parkinsonism

D. Safarpour, M. Mancini, C. Murchison, S. Wood, A. Lesher, J. Duda, J. Morley (Philadelphia, PA, USA)

1:45pm-3:15pm: Effect of Medication Review on Reported Symptoms in Parkinson’s disease Patients

C. Stuijt, T. Laar (Groningen, Netherlands)

1:45pm-3:15pm: Factors Influencing Decision-Making About End of Life Care in Patients With Parkinson’s Disease and Their Family Members

R. Bužgová, R. Kozáková, M. Bar, M. škutová, P. Ressner, P. Bártová (Ostrava, Czech Republic)

1:45pm-3:15pm: Gender gap in scientific granting competitions in movement disorders – insights from a national Canadian funding agency

S. Appel-Cresswell, P. Blanchet, J. Wysocki, R. Postuma (Vancouver, BC, Canada)

1:45pm-3:15pm: Genetics of Parkinson’s in India – Young Onset Parkinson’s Disease (GOPI-YOPD) – A Preliminary Demographic profile

P. Kukkle, V. Goyal, R. Kandadai, R. Borgohain, H. Kumar, A. Mukherjee, A. Biswas, S. Das, U. Muthane, S. Desai, P. Wadia, P. Pal, R. Yadav, V. Ramprasad (Bangalore, India)

1:45pm-3:15pm: Gut Feelings about Parkinson’s Disease: The Influence of the Gut Microbiota in a Rodent Model

A. Gorecki, L. Preskey, M. Bakeberg, J. Kenna, C. Gildenhuys, S. Dunlop, F. Koengten, R. Anderton (Nedlands, Australia)

1:45pm-3:15pm: Healthcare Resource Utilization and Costs of Parkinson’s Disease Dementia With Psychosis in the US Medicare Population

J. Wetmore, H. Yan, M. Irfan, Y. Peng, D. Gilbertson, S. Li, N. Rashid, A. Shim (Minneapolis, MN, USA)

1:45pm-3:15pm: Hemi masticatory spasm (HMS) : Series of 7 cases

D. Radhakrishnan, V. Goyal, G. Shukla, M. Singh (New Delhi, India)

1:45pm-3:15pm: Hemifacial spasm management: 26-year experience

Y. Herrero-Infante, A. Rodriguez-Sanz, J. Mañez-Miró, F. Vivancos-Matellano (Madrid, Spain)

1:45pm-3:15pm: High Content Screening of synucleinopathy in primary cortical neurons : dissecting out the interplay between the basic synuclein pools

F. de Giorgi, E. Bezard, F. Ichas (Bordeaux, France)

1:45pm-3:15pm: Identifying In-Clinic Wearable Sensor Features that Predict Parkinson’s Disease Severity

A. Dowling, A. Mirelman, J. Hausdorff, M. Sela, O. Assais, N. Giladi, J. Cedarbaum (Cambridge, MA, USA)

1:45pm-3:15pm: Impact of subthalamic deep brain stimulation on sensorimotor and motor cortical oscillatory activity in free-moving hemiparkinsonian rats

A. Abdulbaki, T. Doll, J. Krauss, M. Alam, K. Schwabe (Hannover, Germany)

1:45pm-3:15pm: Inflammatory cytokines in Saudi Parkinson cohort

N. Alsomali, E. Al-Ofi, M. Obaid, A. Alrafiah (Riyadh, Saudi Arabia)

1:45pm-3:15pm: Inhibition of mitochondrial complexes induces unique transcriptomic and epigenetic profiles: implications to neurodegeneration induced movement disorders

R. Sathyanarayanan, S. Bharath (Bangalore, India)

1:45pm-3:15pm: Investigation into the causes of reduced caffeine levels in Parkinson’s disease

MI. de Bartolo, G. Leodori, A. Fabbrini, M. Costanzo, D. Belvisi, A. Conte, S. Manetto, A. Ciogli, C. Villani, A. Berardelli, G. Fabbrini (Rome, Italy)

1:45pm-3:15pm: Investigation of the protective efficacy of alpha-synuclein-specific antibodies in a novel neuronal cell model for synucleinopathies

A. Peukert, M. Höllerhage, W. Zago, G. Höglinger (Munich, Germany)

1:45pm-3:15pm: Language characteristics of picture description task by Hebrew speaking patients with Parkinson’s disease

D. Shpunt, S. Naor, N. Diamant, A. Faust-Socher, H. Shabtai, R. Peled, A. Migirov, T. Gurevich, Y. Manor (Tel Aviv, Israel)

1:45pm-3:15pm: Mechanisms underlying therapeutic group singing in persons with Parkinson’s disease

E. Stegemoller, A. Zaman, K. Diaz, E. Shirtcliff, M. Kohut (Ames, IA, USA)

1:45pm-3:15pm: Metabolomic Analysis of Fecal Matter from Parkinsonian Mice

V. Vedam-Mai, E. Gill, J. Koelmel, R. Yost, T. Garrett, M. Okun (Gainesville, FL, USA)

1:45pm-3:15pm: MicroRNA Expression in the Diagnosis of Parkinson’s Disease

J. Roy, D. Guévremont, A. Garvey, N. Cutfield, J. Williams (Dunedin, New Zealand)

1:45pm-3:15pm: Modeling of Parkinson’s disease by damaging dopaminergic neurons

L. Toshpulatova, M. Kulmanova (Tashkent, Uzbekistan)

1:45pm-3:15pm: Movement disorders as a clinical feature of Subacute Sclerosing Pan Encephalitis: Expansion of phenotypic spectrum

D. Dash, M. Tripathi, R. Singh (Delhi, India)

1:45pm-3:15pm: Movement disorders associated with autoimmune encephalitis

A. Chouksey, S. Pandey (New Delhi, India)

1:45pm-3:15pm: Movement Disorders in Post Stroke Patients: A Retrospective Analysis

M. Christie, V. Laticevschi, R. Mehanna (Houston, TX, USA)

1:45pm-3:15pm: Neuropathological findings in a SPG4 gene mutation carrier

S. Forcén, I. Aldecoa, AM. Crespo, O. Ramos, L. Ispierto, R. álvarez, D. Vilas (Badalona, Spain)

1:45pm-3:15pm: Objective quantifiable assessment of nocturnal movements in patients with Parkinson’s disease using a wearable sensor

A. Mirelman, I. Hillel, L. Rochester, A. Nieuwboer, B. Bloem, L. Avanzino, S. Shema-Shiratzki, I. Maidan, T. Herman, J. Cederbaum, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

1:45pm-3:15pm: Opsoclonus and ataxia in the setting of synchronous primary malignancies

H. Leal Bailey, S. Wijemanne Sarathkumara, R. Knightstep (San Antonio, TX, USA)

1:45pm-3:15pm: Parkinson’s disease in Middle East, North Africa and South Asia: Consensus from the MDS Task Force on the Middle East

H. Khalil, L. Chahine, J. Junaid Siddiqui, M. Salari, S. El-Jaafary, Z. Aldaajani, M. Abu Al-Melh, T. Mohammad, M. Abu Snineh, N. Syed, M. Bhatt, M. Habib, M. Habahbeh, S. Tabbal, B. Jeon, J. Bajwa (Irbid, Jordan)

1:45pm-3:15pm: Patient organisation collaboration to advance patient engagement in Parkinson’s research

N. Ratcliffe, K. Schroeder (New York, NY, USA)

1:45pm-3:15pm: Pilot testing of the Integrated Parkinson’s Disease Care Network: feasibility, efficacy outcomes and cost description analysis

T. Mestre, D. Kessler, J. Shen, A. Basndwah, H. Shinawi, C. Nussey, A. Ohman, S. Kumar, D. Côté, C. Liddy, K. Thavorn, M. Taljaard, D. Grimes (Ottawa, ON, Canada)

1:45pm-3:15pm: Plasma membrane Ca2+ Atpase 1 as a candidate to mediate the degeneration of dopaminergic neurons by inflammation in Parkinson’s disease

B. Erhardt, MS. Marcora, A. Delella Ezcurra, J. Casabona, R. Tarelli, L. Frenkel, P. Bochicchio, D. Bodin, B. Silva, V. Cavaliere Candedo, MI. Farías, C. Ferrari, M. Allo, C. Höcht, A. Chernomoretz, E. Castaño, MC. Leal, F. Pitossi (Capital Federal, Argentina)

1:45pm-3:15pm: Post-stroke movement disorders: an analysis of 24 cases

M. Burzhunova, N. Garabova, L. Geraskina (Moscow, Russian Federation)

1:45pm-3:15pm: Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in de-novo diagnosed Parkinson patients

F. Lipsmeier, K. Taylor, E. Volkova-Volkmar, R. Postuma, T. Kilchenmann, D. Wolf, Y. Zhang, W. Cheng, A. Scotland, J. Schjodt-Eriksen, F. Boess, D. Ness, C. Gossens, A. Post, M. Lindemann (Basel, Switzerland)

1:45pm-3:15pm: Prevalence of chronic kidney disease in patients with idiopathic Parkinson’s disease in a tertiary care hospital in Mexico City

S. Isais-Millan, CA. Rojas-Guerrero, A. Arriaga, M. Rodriguez-Violante, D. Zuñiga-Garcia, RO. Millan-Guerrero, V. Campos-Gasga, V. Garcia-Barrera, R. Santos-Montero (Colima, Mexico)

1:45pm-3:15pm: Restless Genital Syndrome in a patient with Dementia with Lewy Body

M. Abu Al-Melh, M. Farghal, B. Al-Failakawii (Kuwait, Kuwait)

1:45pm-3:15pm: Rhythmic disorders in idiopathic RBD: a potential new marker for future PD?

V. Cochen Decock, D. Verbizier, C. Geny, S. Dalla Bella (Montpellier, France)

1:45pm-3:15pm: STAT-ON: a Wearable Inertial System to Objectively Evaluate Motor Symptoms in Parkinson’s Disease

D. Rodriguez-Martin, C. Pérez-López, A. Samà, M. Pié, A. Català, J. Cabestany, A. Rodríguez-Molinero (Vilanova I Geltrú, Spain)

1:45pm-3:15pm: Stiff Limb Syndrome Progressing to Stiff Man Syndrome in a non-diabetic man

T. Ali, D. Ginjupally, Z. Guduru (Lexington, KY, USA)

1:45pm-3:15pm: Study on the effect of levodopa administration on serum zinc levels in Parkinson’s disease patients

H. Matsuyama, K. Matsuura, H. Ishikawa, Y. Hirata, N. Kato, A. Niwa, Y. Narita, H. Tomimoto (Tsu, Japan)

1:45pm-3:15pm: SWALLOWING VIDEOENDOSCOPY IN PATIENTS WITH PARKINSON’S DISEASE WITH DEEP BRAIN STIMULATION

T. Alves, N. Oliveira, G. Diaféria, M. Palumbo, MG. Ghilardi, E. Fonoff, M. Padovani (São Paulo, Brazil)

1:45pm-3:15pm: Systematic Assessment of 10 diagnostic marker candidates in biological fluids for Parkinson’s disease

B. Mollenhauer, R. Gera, N. Kruse, R. Barbour, W. Zago, S. Schade, B. Otte, C. Trenkwalder (South San Francisco, CA, USA)

1:45pm-3:15pm: The cognitive profiles differ among freezing of gait subtypes in Parkinson’s disease

J. Longhurst, J. Caldwell, A. Ritter, V. Mishra, B. Bluett, M. Landers (Las Vegas, NV, USA)

1:45pm-3:15pm: The effect of levodopa on speech in advanced Parkinson’s Disease: acoustic analysis and correlation with motor features and dyskinesia

F. Cavallieri, C. Budriesi, A. Gessani, V. Fioravanti, E. Menozzi, S. Contardi, F. Valzania, F. Antonelli (Reggio Emilia, Italy)

1:45pm-3:15pm: Tongue Myokymia and Earache as a unique presentation Associated with Local Tongue Pathology: A Case Report and Review of Literature

N. Merghany, W. Ibrahim, S. Nasr (Cairo, Egypt)

1:45pm-3:15pm: Trends in first line therapy for PD in Wales: A 16 year observational study

K. Orayj, A. Lacey, A. Akbari, O. Pickrell, E. Lane (Cardiff, United Kingdom)

1:45pm-3:15pm: Update from the international MDSGene initiative: International team science to perform genotype-phenotype correlations for hereditary movement disorders

S. Petkovic, S. Schaake, J. Huang, H. Madoev, A. Rasheed, K. Lohmann, C. Klein, C. Marras (Luebeck, Germany)

1:45pm-3:15pm: Use of syringe driver in End of Life Care in Parkinson’s Disease (PD)

N. Butt, M. Khwaja, A. Chatterjee (Reading, United Kingdom)

1:45pm-3:15pm: Utility of a smartphone app in discretely assessing and monitoring symptoms of Parkinson’s disease

N. Shaafi Kabiri, A. Best, S. Johnson, B. Ho, G. Eden, B. Dupee, M. Fedorovsky, J. Severson, D. Amato, B. Severson, J. Bhangu, J. Cosman, M. Erb, K. Thomas (Boston, MA, USA)

1:45pm-3:15pm: Wearable sensor use and monitoring effect of dopamine replacement therapy on motor parameters in a real life clinical setting

A. Podlewska, D. van Wamelen, A. Sauerbier, V. Leta, D. Trivedi, M. Parry, K. Ray Chaudhuri (Lodnon, United Kingdom)

1:45pm-3:15pm: Wearable versus marker-free technologies: does it matter for clinical gait analysis?

K. Otte, D. Drebinger, H. Röhling, T. Vater, D. Kroneberg, M. Voigt, B. Kayser, S. Mansow-Model, AU. Brandt, F. Paul, A. Lipp, T. Schmitz-Hübsch (Berlin, Germany)

1:45pm-3:15pm: Wide distribution of alpha-synuclein oligomers in Creutzfeldt-Jakob disease detected by a novel proximity ligation assay

R. Valenti-Azcarate, I. Martinez-Valbuena, C. Caballero, I. Marcilla Garcia, G. Marti, M. Carmona-Abellan, M. Tuñon-Alvarez, MR. Luquin-Piudo (Pamplona, Spain)

« View all sessions from the 2019 International Congress.